Sierra Oncology Inc logo

SRRA - Sierra Oncology Inc Share Price

$10.76 -0.6  -5.6%

Last Trade - 21/09/20

Small Cap
Market Cap £91.8m
Enterprise Value £-3.66m
Revenue £n/a
Position in Universe 4193rd / 6392
Unlock SRRA Revenue
Relative Strength (%)
1m -12.2%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -48.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Sierra Oncology Inc revenues was not reported. Net loss increased 73% to $48.4M. Higher net loss reflects Stock-Based Compensation in SGA increase from $1M to $3.1M (expense), General and administrative increase of 34% to $7.7M (expense), Research and development - Balancing val increase of 4% to $20.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


SRRA Revenue Unlock SRRA Revenue

Net Income

SRRA Net Income Unlock SRRA Revenue

Normalised EPS

SRRA Normalised EPS Unlock SRRA Revenue

PE Ratio Range

SRRA PE Ratio Range Unlock SRRA Revenue

Dividend Yield Range

SRRA Dividend Yield Range Unlock SRRA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SRRA EPS Forecasts Unlock SRRA Revenue
Profile Summary

Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated May 8, 2003
Public Since July 16, 2015
No. of Shareholders: n/a
No. of Employees: 71
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 10,395,732
Free Float (0.0%)
Eligible for
SRRA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for SRRA
Upcoming Events for SRRA
Frequently Asked Questions for Sierra Oncology Inc
What is the Sierra Oncology Inc share price?

As of 21/09/20, shares in Sierra Oncology Inc are trading at $10.76, giving the company a market capitalisation of £91.8m. This share price information is delayed by 15 minutes.

How has the Sierra Oncology Inc share price performed this year?

Shares in Sierra Oncology Inc are currently trading at $10.76 and the price has moved by -38.71% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sierra Oncology Inc price has moved by -45.37% over the past year.

What are the analyst and broker recommendations for Sierra Oncology Inc?

Of the analysts with advisory recommendations for Sierra Oncology Inc, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Sierra Oncology Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Sierra Oncology Inc next release its financial results?

Sierra Oncology Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Sierra Oncology Inc dividend yield?

Sierra Oncology Inc does not currently pay a dividend.

Does Sierra Oncology Inc pay a dividend?

Sierra Oncology Inc does not currently pay a dividend.

When does Sierra Oncology Inc next pay dividends?

Sierra Oncology Inc does not currently pay a dividend.

How do I buy Sierra Oncology Inc shares?

To buy shares in Sierra Oncology Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Sierra Oncology Inc?

Shares in Sierra Oncology Inc are currently trading at $10.76, giving the company a market capitalisation of £91.8m.

Where are Sierra Oncology Inc shares listed? Where are Sierra Oncology Inc shares listed?

Here are the trading details for Sierra Oncology Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: SRRA
What kind of share is Sierra Oncology Inc?

Based on an overall assessment of its quality, value and momentum, Sierra Oncology Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Sierra Oncology Inc share price forecast 2020?

Shares in Sierra Oncology Inc are currently priced at $10.76. At that level they are trading at 0.126% discount to the analyst consensus target price of 0.00.

Analysts covering Sierra Oncology Inc currently have a consensus Earnings Per Share (EPS) forecast of -7.64 for the next financial year.

How can I tell whether the Sierra Oncology Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sierra Oncology Inc. Over the past six months, the relative strength of its shares against the market has been -19%. At the current price of $10.76, shares in Sierra Oncology Inc are trading at -10.59% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Sierra Oncology Inc PE Ratio?

We were not able to find PE ratio data for Sierra Oncology Inc.

Who are the key directors of Sierra Oncology Inc?

Sierra Oncology Inc's management team is headed by:

Sukhi Jagpal - CFO
Barbara Klencke - OTH
Robert Pelzer - CHM
Jeffrey Cooper - IND
Mark Kowalski - OTH
Andrew Allen - IND
Gaurav Aggarwal - IND
Mona Ashiya - IND
Stephen Dilly - PRE
Craig Collard - DRC
Christina Thomson - GCN
Kevin Norrett - OTH
William Turner - OTH
Who are the major shareholders of Sierra Oncology Inc?

Here are the top five shareholders of Sierra Oncology Inc based on the size of their shareholding:

Vivo Capital, LLC Venture Capital
Percentage owned: 18.44% (1.92m shares)
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 14.21% (1.48m shares)
Longitude Capital Management Co., LLC Venture Capital
Percentage owned: 14.21% (1.48m shares)
Abingworth Management Limited Venture Capital
Percentage owned: 8.43% (877k shares)
Caxton Associates LP Hedge Fund
Percentage owned: 6.19% (644k shares)
Similar to SRRA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.